The following is a summary of the Matinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Call Transcript:

Financial Performance:

• Matinas BioPharma reported a revenue of $1.1 million for 2023, primarily generated from collaborations with BioNTech and Genentech.

• Major expenses for the year amounted to $24.9 million, decreased from $27.8 million in 2022, mainly due to lower clinical trial expenses.

• The net loss for 2023 was estimated at $22.9 million or $0.11 per share, up from a net loss of $21.0 million or $0.10 in the prior year.

• The company reported income from selling unused New Jersey net operating losses and R&D tax credits of $0.5 million in 2023.

• Cash, cash equivalents, and marketable securities worth $13.8 million were part of company's holdings as of December 2023.

Business Progress:

• Matinas is in partnership discussions, aiming to advance MAT2203 into Phase III.

• Positive results were reported from the Compassionate/Expanded Use Access Program.

• The focus has been on advancements of MAT2203 and the lipid nano-crystal (LNC) platform.

• The LNC platform has shown promise with the potent chemotherapeutic agent, docetaxel.

• The company showed progress in research for understanding LNC uptake and effective cargo delivery within tumor cell lines.

• The company continues to maintain its presence on the NYSE American and is preparing for the upcoming milestones in Q2 of 2024.

More details: Matinas BioPharma IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.